The benefit of antiplatelet therapy remains unclear, although it does appear that aspirin monotherapy started within 48 hours of stroke onset may result in a modest clinical improvement. Glicoprotein (GP) IIb/IIIa antagonists are currently considered the most powerful specific inhibitors of platelet activation in acute thrombosis. Glicoprotein IIb/IIIa inhibitor therapy could merit a prominent role also in the initial management of patients with acute ischemic stroke. Abciximab may be promising in this setting and should be evaluated in further clinical trials.
Glicoprotein (GP) IIb/IIIa inhibitors for acute stroke treatment
Paciaroni MSecondo
;
2002
Abstract
The benefit of antiplatelet therapy remains unclear, although it does appear that aspirin monotherapy started within 48 hours of stroke onset may result in a modest clinical improvement. Glicoprotein (GP) IIb/IIIa antagonists are currently considered the most powerful specific inhibitors of platelet activation in acute thrombosis. Glicoprotein IIb/IIIa inhibitor therapy could merit a prominent role also in the initial management of patients with acute ischemic stroke. Abciximab may be promising in this setting and should be evaluated in further clinical trials.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
